The merger is complete and the stock is being deregistered. Existing shareholders should have already tendered shares at $85.00 or will receive the merger consideration through the paying agent. No further trading in CRNX on Nasdaq is possible. Monitor for any remaining merger-related distributions or tax documents from the depositary.
Price Chart
Executive Summary
Crinetics Pharmaceuticals filed Form 15-12G to terminate its SEC registration under Section 12(g), effective September 11, 2026, following the completion of its acquisition by Vertex Pharmaceuticals at $85.00 per share. The filing confirms only one holder of record remains, making this a routine procedural step after the merger closed. This deregistration is the final administrative action exiting public markets, consistent with the prior Nasdaq delisting filing (Form 25-NSE).
Key Facts
- Form 15-12G filed September 11, 2026 to terminate SEC registration under Section 12(g).
- Approximate number of holders of record as of certification date: One (1).
- Deregistration follows the all-cash acquisition by Vertex Pharmaceuticals at $85.00 per share, aggregate consideration approximately $10.0 billion.
- Nasdaq delisting (Form 25-NSE) filed September 1, 2026 — complete exit from public markets.
- President Charles Wagner signed the filing on behalf of the company.
Financial Impact
All-cash acquisition by Vertex Pharmaceuticals at $85.00 per share, aggregate consideration approximately $10.0 billion.
Risk Factors
- No further public trading — shareholders must have tendered shares to receive $85.00 per share.
- Potential delays in receiving merger consideration if shares were not properly tendered.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 15-12G Filing (CRNX) — Batch item 1 | 0001140361-26-036281 |
| Document: 0001140361-26-036281-index-headers.html | 0001140361-26-036281 |
| Document: 0001140361-26-036281-index.html | 0001140361-26-036281 |
| Document: 0001140361-26-036281.txt | 0001140361-26-036281 |
| 15-12G Filing (CRNX) — Batch item 5 | 0001140361-26-036281 |
| Document: 0001140361-26-036281-index-headers.html | 0001140361-26-036281 |
| Document: 0001140361-26-036281-index.html | 0001140361-26-036281 |
| Document: 0001140361-26-036281.txt | 0001140361-26-036281 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | 15-12G | — | awaiting T+1 | — | — |
Sep 1, 2026 4w ago | 25-NSE | $84.95 $84.95 | · 0.00% | ▼ −0.44% | — |
Sep 1, 2026 4w ago | 8-K | $84.95 $84.95 | · 0.00% | ▼ −0.44% | — |
Aug 14, 2026 7w ago | 8-K | $84.70 $84.75 | ▲ +0.06% | ▲ +0.53% | — |
Aug 3, 2026 8w ago | Press Release | $83.86 $84.00 | ▲ +0.17% | ▲ +0.37% | — |
Jul 10, 2026 12w ago | DEFA14A | $83.67 $83.71 | ▲ +0.05% | ▼ −0.31% | — |
Jul 10, 2026 12w ago | 8-K | $83.67 $83.71 | ▲ +0.05% | ▼ −0.31% | — |
Jun 30, 2026 13w ago | Press Release | $38.68 $42.23 | ▲ +9.18% | ▲ +9.31% | — |
Jun 14, 2026 15w ago | Press Release | $35.12 $35.00 | ▼ −0.34% | ▲ +0.25% | — |
Jun 14, 2026 15w ago | Press Release | $35.12 $35.00 | ▼ −0.34% | ▲ +0.25% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access